Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets: Comparative Pharmacology and Role in Elective PCI

Interv Cardiol Clin. 2013 Oct;2(4):527-535. doi: 10.1016/j.iccl.2013.05.010.

Vijay Kunadian ¹, Hannah Sinclair ², Aaron Sutton ², George D Dangas ³

Affiliations

1 Faculty of Medical Sciences, Institute of Cellular Medicine, Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: [email protected].
2 Faculty of Medical Sciences, Institute of Cellular Medicine, Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
3 Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.

PMID: 28582181 DOI: 10.1016/j.iccl.2013.05.010

Abstract

Angina pectoris accounts for a large burden of disease worldwide. Antiplatelet agents play a crucial role in inhibiting the platelet response to vascular injury after percutaneous coronary intervention (PCI) for the management of coronary artery disease. Antiplatelet agents are also essential in the longer term, because the metallic structure of stents is inherently thrombogenic. This article examines the use of aspirin, P2Y12 inhibitors, and Other oral antiplatelets in the setting of elective PCI. Dual antiplatelet therapy in elective PCI is now standard therapy. The clinical use of novel antiplatelet therapy in the setting requires further evaluation.

Keywords

Antiplatelet agents; Elective angioplasty; Percutaneous coronary intervention.

Name
Email *

	Sorry, but the email address you supplied was invalid.